Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Immune Modulation by Exosomes in COVID-19

Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Who May Be Eligible (Plain English)

Who May Qualify: - Critically ill COVID-19 patients with lung dysfunction - COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020) - Body weight \> 50 kg - willing to sign a consent form Who Should NOT Join This Trial: - Pregnant or breast feeding women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Critically ill COVID-19 patients with lung dysfunction * COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020) * Body weight \> 50 kg * Informed consent Exclusion Criteria: * Pregnant or breast feeding women

Treatments Being Tested

BIOLOGICAL

Application of exosomes in a whole blood assay

Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.

Locations (1)

Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine
Ulm, Germany